Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma

Cancer. 1971 Aug;28(2):306-17. doi: 10.1002/1097-0142(197108)28:2<306::aid-cncr2820280208>3.0.co;2-n.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Bone Marrow Examination
  • Child
  • Child, Preschool
  • Cyclophosphamide / administration & dosage*
  • Cyclophosphamide / adverse effects
  • Drug Synergism*
  • Female
  • Hodgkin Disease / classification
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / mortality
  • Hodgkin Disease / radiotherapy
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / classification
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • Lymphoma, Non-Hodgkin / classification
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / mortality
  • Lymphoma, Non-Hodgkin / radiotherapy
  • Male
  • Middle Aged
  • Prednisone / administration & dosage*
  • Prednisone / adverse effects
  • Remission, Spontaneous
  • Sex Factors
  • Vincristine / administration & dosage*
  • Vincristine / adverse effects

Substances

  • Vincristine
  • Cyclophosphamide
  • Prednisone